Anika Therapeutics (ANIK) Income towards Parent Company (2010 - 2025)
Anika Therapeutics (ANIK) posted quarterly Income towards Parent Company of -$1.5 million for Q4 2025, up 92.21% year-over-year from -$785065.7 in Q4 2024, and down 278.37% quarter-over-quarter from $846000.0 in Q3 2025.
Anika Therapeutics (ANIK) Income towards Parent Company (2010 - 2025) Analysis & Trends
Anika Therapeutics (ANIK) has reported Income towards Parent Company for 16 consecutive years, with -$1.5 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Income towards Parent Company rose 92.21% year-over-year to -$1.5 million; the TTM figure through Jun 2026 stood at -$663000.0 (up 98.61% YoY), while the FY2025 annual figure was -$901000.0, up 98.11% from the prior year.
- Income towards Parent Company declined to -$1.5 million in Q4 2025 per ANIK's latest filing, from $846000.0 in the prior quarter.
- Across five years, Income towards Parent Company topped out at $16.2 million in Q4 2023 and bottomed at -$28.1 million in Q3 2024.
- Historically, Income towards Parent Company has averaged -$2.3 million across 5 years, with a median of -$2.0 million in 2024.
- On a YoY basis, Income towards Parent Company climbed as much as 411.38% in 2022 and fell as far as 853.99% in 2022.
- Anika Therapeutics' Income towards Parent Company stood at -$3.2 million in 2021, then surged by 411.38% to $10.1 million in 2022, then surged by 60.71% to $16.2 million in 2023, then tumbled by 219.74% to -$19.4 million in 2024, then jumped by 92.21% to -$1.5 million in 2025.
- Business Quant data shows ANIK's Income towards Parent Company at -$1.5 million in Q4 2025, $846000.0 in Q3 2025, and $677000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - |
| 2 | Teva Pharmaceutical Industries | 42.98 Bn | 39.33 Bn | 2.15 Bn |
| 3 | Zoetis | 31.54 Bn | 29.86 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.15 Bn | 19.48 Bn | 683.80 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.74 Bn | 11.21 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - |
| 10 | Anika Therapeutics | 282.86 Mn | 244.45 Mn | 21.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -1.51 Mn |
| Sep 30, 2025 | 846,000.00 |
| Jun 30, 2025 | 677,000.00 |
| Mar 31, 2025 | -915,000.00 |
| Dec 31, 2024 | -19.38 Mn |
| Sep 30, 2024 | -28.07 Mn |
| Jun 30, 2024 | 2.45 Mn |
| Mar 31, 2024 | -2.56 Mn |
| Dec 31, 2023 | 16.18 Mn |
| Sep 30, 2023 | -6.54 Mn |
| Jun 30, 2023 | -2.74 Mn |
| Mar 31, 2023 | -10.31 Mn |
| Dec 31, 2022 | 10.07 Mn |
| Sep 30, 2022 | -4.16 Mn |
| Jun 30, 2022 | -2.84 Mn |
| Mar 31, 2022 | -2.91 Mn |
| Dec 31, 2021 | -3.23 Mn |
| Sep 30, 2021 | 552,000.00 |
| Jun 30, 2021 | 6.53 Mn |
| Mar 31, 2021 | 2.84 Mn |